Swedes win on the EU patent but other tough questions pass to Spain
This article was originally published in Scrip
When the Swedes assumed the six-month presidency of the EU Council of Ministers in July, they vowed that by the end of the year they would have made progress on a number of areas of direct relevance to the biopharmaceutical industry. To their credit, they have managed to get the member states to agree on contentious issues such as the single EU patent, but success in other areas has proved more elusive.
You may also be interested in...
The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.